News archive
October 2026
-
Story Education and Awareness
The Novartis Teen Corporate Mentoring Program: How we’re building the next generation of leaders
At this year’s event, over 100 students gathered to learn about how AI is shaping healthcare, future careers in science, medicine, law, and business—and an important life lesson from NFL player, Chris Manhertz.
-
Media Release
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion1,2 MRI… -
Media Release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3… -
Story Education and Awareness
5 things you didn't know about B cells and autoimmune disease
B cells are immune cells that help fight infection, but when they go rogue, they can drive autoimmune diseases like Sjögren's. Here's what to know.
-
Story Global Impact Access to Healthcare
Fortune includes Novartis in 2026 Change The World List for malaria program
For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.
-
Story Global Impact
Community health takes a village: from Pulpit to Pew
Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.
-
Media Release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21 SD is most prevalent type of chronic… -
Media Release
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and…
September 2026
-
Story Hope
Why Improving Heart Health Starts In Our Communities
Learn more about HeART, a five-year partnership between Novartis and Meharry Medical College focused on improving cardiovascular health in three US cities. Liz McGee, Global Head of Inclusive Health Accelerators, Novartis, reflects on how health starts with listening to the people closest to the challenge.
-
Story Hope
Beyond Breast Cancer: Making Lived Experiences More Visible
Breast cancer doesn’t stop when treatment ends. For many, its most enduring challenges remain under recognized and undiscussed. Through Letters Between Us and ongoing community engagement, Novartis is sharing real patient stories to highlight the power of community connection and inspire strength in others.
In Letters Between Us, people impacted by breast cancer wrote letters about what they had learned since a breast cancer diagnosis. Learn more about their experience at Camp Breastie, a community-based organization.
-
Story Education and Awareness
Beyond Platelet Counts: What Survey Data Reveals about Real ITP Patient Needs and Success
Learn how fatigue, emotional wellbeing, and shared decision-making shape patient-centered care for those living with immune thrombocytopenia (ITP).